Innate Pharma SA (OTCMKTS:IPHYF) Sees Significant Decrease in Short Interest

Innate Pharma SA (OTCMKTS:IPHYF) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 3,770 shares, a decline of 51.8% from the July 15th total of 7,824 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.

Innate Pharma Stock Performance

Shares of IPHYF remained flat at $1.65 during mid-day trading on Friday. Innate Pharma has a 1 year low of $1.37 and a 1 year high of $2.25. The business’s 50-day moving average price is $1.65 and its two-hundred day moving average price is $1.78.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.